Taylor Morrison Home
TMHC
Meritage Homes
MTH
D.R. Horton
DHI
Lennar Corp
LEN
Toll Brothers
TOL
US Stock MarketDetailed Quotes
CABA Cabaletta Bio
- 1.980
- +0.020+1.02%
Close Feb 25 16:00 ET
- 1.990
- +0.010+0.51%
Post 20:01 ET
96.78MMarket Cap-0.92P/E (TTM)
2.010High1.920Low934.22KVolume1.950Open1.960Pre Close1.84MTurnover2.25%Turnover RatioLossP/E (Static)48.88MShares23.98052wk High0.56P/B82.30MFloat Cap1.76052wk Low--Dividend TTM41.57MShs Float26.350Historical High--Div YieldTTM4.59%Amplitude0.590Historical Low1.971Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Cabaletta Bio Stock Forum
“Title: Clinical and Translational Studies of Rese-cel (an anti-CD19 CAR T Therapy) in Myositis, SLE, and Systemic Sclerosis: RESET Phase I/II Trials
Date and Time: Saturday, February 22, 2025, 10:15 a.m. – 10:30 a.m. CET
*Additional information can be accessed on the website of each scientific meeting. Presentation materials will be made available on the Posters & Publications section of the Company's website following each event.
About rese-cel (formerly referred to ...
The latest clinical data from Cabaletta Bio's rese-cel program represents a significant milestone in autoimmune disease treatment. The achievement of DORIS remission in 3 out of 4 SLE patients, complete renal response in lupus nephritis, and sustained improvement in dermatomyositis - all while discontinuing immunosuppressants - suggests a potentially transformative therapeutic approach.
The confirmed deep B cell depletion, both in circulation and ...
Breakthrough Clinical Results: Rese-cel Treatment Achieves Remission in Lupus Patients, Shows Promise Across Autoimmune Disorders
Revolutionary Autoimmune Treatment Success: Patients Achieve Complete Remission, Stop All Medications
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses Across Multiple Indications With Rese-Cel at February Scientific Meetings
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
Tuesday, 18th February at 7:00 am
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosu...
No comment yet